The effect of nitrogen source and cysteine on the morphology, conidiation and a cell wall fraction of conidial and aconidial Neurospora crassa.

D. E. Bianchi,G. Turian

DOI: https://doi.org/10.1002/JOBM.19670070403

Zeitschrift für allgemeine Mikrobiologie

Abstract:

What problem does this paper attempt to address?

Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis

Masahito Shimizu,Yohei Shirakami,Kenji Imai,Koji Takai,Hisataka Moriwaki

DOI: https://doi.org/10.4103/1477-3163.100398

Abstract:One of the key features of hepatocellular carcinoma (HCC) is the high rate of intrahepatic recurrence that correlates with poor prognosis. Therefore, in order to improve the clinical outcome for patients with HCC, development of a chemopreventive agent that can decrease or delay the incidence of recurrence is a critical issue for urgent investigation. Acyclic retinoid (ACR), a synthetic retinoid, successfully improves HCC patient survival by preventing recurrence and the formation of secondary tumors. A malfunction of the retinoid X receptor-α (RXRα) due to phosphorylation by the Ras-MAPK signaling pathway plays a critical role in liver carcinogenesis, and ACR exerts chemopreventive effects on HCC development by inhibiting RXRα phosphorylation. Here, we review the relationship between retinoid signaling abnormalities and liver disease, the mechanisms of how RXRα phosphorylation contributes to liver carcinogenesis, and the detailed effects of ACR on preventing HCC development, especially based on the results of our basic and clinical research. We also outline the concept of "clonal deletion and inhibition" therapy, which is defined as the removal and inhibition of latent malignant clones from the liver before they expand into clinically detectable HCC, because ACR prevents the development of HCC by implementing this concept. Looking toward the future, we discuss "combination chemoprevention" using ACR as a key drug since it can generate a synergistic effect, and may thus be an effective new strategy for the prevention of HCC.
Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: basic aspects, clinical applications, and future prospects

Masahito Shimizu,Kenji Imai,Koji Takai,Hisataka Moriwaki

2012-11-01

Abstract:The poor prognosis for hepatocellular carcinoma (HCC) is associated with its high rate of recurrence in the cirrhotic liver. Therefore, development of effective strategies for preventing recurrence and secondary tumors will improve the clinical outcome of HCC patients. A malfunction of the retinoid X receptor-α (RXRα) due to phosphorylation by the Ras-MAPK signaling pathway is profoundly associated with liver carcinogenesis, and thus, may be a promising target for HCC chemoprevention. Acyclic retinoid (ACR), which inhibits Ras-MAPK activation and RXRα phosphorylation, successfully prevents HCC recurrence, thus improving patient survival. The fundamental concept of HCC chemoprevention by ACR is "clonal deletion," which is defined as the removal of latent malignant clones from the liver before they expand into clinically detectable HCC. "Combination chemoprevention" using ACR as a key drug holds great promise of a new effective strategy for the prevention of HCC because of its synergism. ACR is also expected to prevent the development of HCC in obese people, who are at an increased risk to HCC, because this agent significantly inhibits obesity-related liver tumorigenesis in the rodent model. Here, we review the detailed effects of ACR on preventing HCC development, especially based on the results of our basic and clinical research.
Intraperitoneal Rupture of Hepatic Hydatid Cyst Following Blunt Abdominal Trauma

A. Dhua,Akshay Sharma,Y. Sarin

2012-01-05

APSP Journal of Case Reports

Abstract:Peritonitis due to rupture of liver hydatid cyst secondary to blunt abdominal trauma can present with fatal consequences. Timely diagnosis and appropriate surgical management can be life saving. We report a case of ruptured liver hydatid cyst in the peritoneal cavity following trauma and its successful operative management in a preadolescent previously asymptomatic boy. Importance of detailed physical examination and early diagnosis by using appropriate radiological investigations is highlighted.
Exploring the reactivity of N-alkynylated sulfoximines: [2 + 2]-cycloadditions.

Ramona Pirwerdjan,D. Priebbenow,P. Becker,Philip Lamers,C. Bolm

DOI: https://doi.org/10.1021/ol4026028

IF: 5.2

2013-10-23

Organic Letters

Abstract:To assess the potential of N-alkynylated sulfoximines as new (chiral) reagents for organic synthesis, their reactivity profile in numerous synthetic processes is under investigation. When reacted with ketenes, the alkynylated-sulfoximines undergo a [2 + 2]-cycloaddition process to afford sulfoximine-functionalized cyclobutenones in excellent yields.
Combination of acyclic retinoid with branched-chain amino acids inhibits xenograft growth of human hepatoma cells in nude mice

Masahito Shimizu,Yohei Shirakami,Hiroyasu Sakai,Junpei Iwasa,Makoto Shiraki,Koji Takai,Takafumi Naiki,Hisataka Moriwaki

DOI: https://doi.org/10.1111/j.1872-034X.2012.01045.x

Abstract:Aim: Combination chemoprevention is a promising strategy to improve the prognosis of hepatocellular carcinoma (HCC). A malfunction of retinoid X receptor-α (RXR-α) due to phosphorylation by Ras/mitogen-activated protein kinase is closely associated with liver carcinogenesis and acyclic retinoid (ACR) can prevent HCC development by inhibiting RXR-α phosphorylation. The present study examined the possible combined effects of ACR plus branched-chain amino acids (BCAA), which can also prevent the development of HCC in obese patients with liver cirrhosis, in human HCC xenografts in nude mice. Methods: This study examined the effects of the combination of ACR plus BCAA on the growth of Huh7 human HCC xenografts in nude mice. The effects of the combination on the phosphorylation of RXR-α, extracellular signal-regulated kinase (ERK), Akt and insulin-like growth factor-1 receptor (IGF-1R) proteins, and on the expression levels of retinoic acid receptor-β (RAR-β) and p21(CIP1) mRNA, were also examined by western blot and real-time reverse transcription polymerase chain reaction analyses, respectively. Results: The combined treatment with ACR plus BCAA significantly inhibited the growth of Huh7 xenografts. The combination of these agents caused a marked inhibition of the phosphorylation of RXR-α, ERK, Akt and IGF-1R proteins in the xenografts. In addition, the expression levels of RAR-β and p21(CIP1) mRNA significantly increased by these agents. Conclusion: The combination of ACR and BCAA restores the function of RXR-α by inhibiting its phosphorylation and increasing the level of RAR-β, a heterodimeric partner for RXR-α, and thus suppresses the growth of HCC xenografts. Therefore, this combination might be an effective regimen for the treatment and, probably, chemoprevention of HCC.
Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids

Masahito Shimizu,Yohei Shirakami,Tatsunori Hanai,Kenji Imai,Atsushi Suetsugu,Koji Takai,Makoto Shiraki,Hisataka Moriwaki

DOI: https://doi.org/10.1002/mnfr.201300538

Abstract:The poor prognosis for patients with hepatocellular carcinoma (HCC) is associated with its high rate of recurrence in the cirrhotic liver. Therefore, more effective strategies need to be urgently developed for the chemoprevention of this malignancy. The malfunction of retinoid X receptor α, a retinoid receptor, due to phosphorylation by Ras/mitogen-activated protein kinase is closely associated with liver carcinogenesis and may be a promising target for HCC chemoprevention. Acyclic retinoid (ACR), a synthetic retinoid, can prevent HCC development by inhibiting retinoid X receptor α phosphorylation and improve the prognosis for this malignancy. Supplementation with branched-chain amino acids (BCAA), which are used to improve protein malnutrition in patients with liver cirrhosis, can also reduce the risk of HCC in obese cirrhotic patients. In experimental studies, both ACR and BCAA exert suppressive effects on HCC development and the growth of HCC cells. In particular, combined treatment with ACR and BCAA cooperatively inhibits the growth of HCC cells. Furthermore, ACR and BCAA inhibit liver tumorigenesis associated with obesity and diabetes, both of which are critical risk factors for HCC development. These findings suggest that pharmaceutical and nutraceutical approaches using ACR and BCAA may be promising strategies for preventing HCC and improving the prognosis of this malignancy.
Retinoid roles in blocking hepatocellular carcinoma

Yohei Shirakami,Hiroyasu Sakai,Masahito Shimizu

DOI: https://doi.org/10.3978/j.issn.2304-3881.2015.05.01

Abstract:Hepatocellular carcinoma (HCC) is a major health issue in many countries. The prognosis of HCC is still poor due to its high recurrence rate and its resistance to chemotherapy. Retinoids have long been known to have a connection with liver diseases, including HCC. Many experimental and clinical investigations have demonstrated associations between retinoids and hepatic disease, including the loss of retinoid activity in HCC cell lines and decreased hepatic retinoid stores and altered retinoid signaling in patients with cirrhosis and HCC. Based on these findings, preclinical and clinical investigations of retinoid effects on HCC have been undertaken. Recently, clinical trial results for the use of a synthetic retinoid, acyclic retinoid (ACR), to prevent HCC recurrence were published. In addition, extensive experimental studies on the action of retinoids in liver disease, including chronic viral hepatitis and non-alcoholic fatty liver disease (NAFLD), which lead to HCC have been performed. In the first section of this review, we will summarize the effectiveness and roles of retinoid for treating liver disease and blocking HCC. Subsequently, we will focus on ACR actions in blocking HCC.
Covert Channel Analysis of the Password-Capability System

D. Mossop,R. Pose

DOI: https://doi.org/10.1007/11572961_53

2005-10-24

Abstract:
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells

Toh Kanamori,Masahito Shimizu,Masataka Okuno,Rie Matsushima-Nishiwaki,Hisashi Tsurumi,Soichi Kojima,Hisataka Moriwaki

DOI: https://doi.org/10.1111/j.1349-7006.2006.00384.x

Abstract:Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide. However, effective chemopreventive and chemotherapeutic agents for this cancer have not yet been developed. In clinical trials acyclic retinoid (ACR) and vitamin K(2) (VK(2)) decreased the recurrence rate of HCC. In the present study we examined the possible combined effects of ACR or another retinoid 9-cis retinoic acid (9cRA) plus VK(2) in the HuH7 human HCC cell line. We found that the combination of 1.0 microM ACR or 1.0 microM 9cRA plus 10 microM VK(2) synergistically inhibited the growth of HuH7 cells without affecting the growth of Hc normal human hepatocytes. The combined treatment with ACR plus VK(2) also acted synergistically to induce apoptosis in HuH7 cells. Treatment with VK(2) alone inhibited phosphorylation of the retinoid X receptor (RXR)alpha protein, which is regarded as a critical factor for liver carcinogenesis, through inhibition of Ras activation and extracellular signal-regulated kinase phosphorylation. Moreover, the inhibition of RXRalpha phosphorylation by VK(2) was enhanced when the cells were cotreated with ACR. The combination of retinoids plus VK(2) markedly increased both the retinoic acid receptor responsive element and retinoid X receptor responsive element promoter activities in HuH7 cells. Our results suggest that retinoids (especially ACR) and VK(2) cooperatively inhibit activation of the Ras/MAPK signaling pathway, subsequently inhibiting the phosphorylation of RXRalpha and the growth of HCC cells. This combination might therefore be effective for the chemoprevention and chemotherapy of HCC.
Novel role of 4-hydroxy-2-nonenal in AIFm2-mediated mitochondrial stress signaling.

Sumitra Miriyala,Sumitra Miriyala,Chadinee Thippakorn,L. Chaiswing,L. Chaiswing,Yong Xu,T. Noel,Artak Tovmasyan,I. Batinic-Haberle,C. V. Kooi,Wang Chi,A. Latif,M. Panchatcharam,V. Prachayasittikul,D. Butterfield

DOI: https://doi.org/10.1016/j.freeradbiomed.2015.12.002

2016-02-01

Abstract:
β-Carotene-Induced Changes in RARβ Isoform mRNA Expression Patterns Do Not Influence Lung Adenoma Multiplicity in the NNK-Initiated A/J Mouse Model

R. Góralczyk,H. Bachmann,K. Wertz,B. Lenz,G. Riss,Petra Buchwald Hunziker,Bradley W. Greatrix,C. Aebischer

DOI: https://doi.org/10.1207/s15327914nc5402_12

2006-07-01

Nutrition and Cancer

Abstract:Abstract: A number of epidemiological studies have reported associations of β-carotene plasma levels or intake with decreased lung cancer risk. However, intervention studies in smokers reported increased lung tumor rates after high long-term β-carotene supplementation. For insight into these conflicting results, we studied the influence of β-carotene on tobacco smoke carcinogen-induced lung cancer development in the A/J-mouse using 4-(N-Methyl-N-nitro samino)-1-(3-pyridyl)-1-butanone (NNK) as the initiator and lung adenoma multiplicity as the functional endpoint. Gene regulation of the putative tumor suppressor RARβ in mouse lung was analyzed by quantitative real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for its relevance in predicting the endpoint of lung cancer. A/J-mice achieved plasma β-carotene levels of up to 3 μmol/L within 4 wk and up to 6 μmol/L after 6 mo of supplementation on a diet modified to enhance β-carotene absorption. Despite high lung β-carotene concentrations of up to 6 μmol/kg, tumor multiplicity was not significantly affected by the β-carotene treatment, either in carcinogen-initiated or non-initiated mice, and was unrelated to β-carotene dose and the time point of treatment during cancer formation. Tumor multiplicity did not correlate with β-carotene plasma levels in NNK-treated animals. All RARβ isoforms were significantly suppressed in the lungs of NNK- and NNK plus high dose β-carotene-treated animals. However, the number of tumors per mouse did not correlate with the RARβ-isoform expression levels. β-carotene alone after 3 mo of supplementation mildly but significantly increased levels of RARβ1, β2, and β4. This increase persisted for 6 mo for RARβ2 and β4. In summary, we found no effect of β-carotene on tumor formation in the NNK-initiated A/J-mouse lung cancer model with respect to dose or time point of treatment. β-Carotene-induced changes in RARβ isoform gene expression levels were not predictive for the number of lung tumors but were indicative of intact β-carotene metabolism and persistent sensitivity to retinoic acid in the mice. Down-regulation of RARβ in NNK-induced adenoma-bearing lungs was similar to that observed in human lung cancer and further confirms the A/J-mouse as a valuable model for lung carcinogenesis.
Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells

Hideharu Tatebe,Masahito Shimizu,Yohei Shirakami,Hiroyasu Sakai,Yoichi Yasuda,Hisashi Tsurumi,Hisataka Moriwaki

DOI: https://doi.org/10.1016/j.canlet.2009.05.019

2009-11-28

Abstract:A malfunction of retinoid X receptor-alpha (RXRalpha) due to phosphorylation is associated with the development of hepatocellular carcinoma (HCC) and acyclic retinoid (ACR), which targets RXRalpha, can prevent the development of second primary HCC. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induces apoptosis and cell cycle arrest in cancer cells. VPA can also enhance the sensitivity of cancer cells to retinoids. The present study examined the possible combined effects of ACR plus VPA in HepG2 human HCC cell line. The combination of 5muM ACR and 1mM VPA, about the IC(25) value for both compounds, synergistically inhibited the growth of HepG2 cells without affecting the growth of Hc normal human hepatocytes. The combined treatment with ACR plus VPA also acted synergistically to induce apoptosis and G(0)-G(1) cell cycle arrest in HepG2 cells. This combination further exerted a synergistic inhibition of the phosphorylation of RXRalpha, ERK, Akt and GSK-3beta proteins and caused an accumulation of acetylated histones H3 and H4 proteins. VPA enhanced the ability of ACR to raise the cellular levels of RARbeta and p21(CIP1). The combination of these agents markedly increased both the RARE and RXRE promoter activities in HepG2 cells. These results suggest that ACR and VPA cooperatively increase the expression of RARbeta and p21(CIP1), while inhibiting the phosphorylation of RXRalpha, and these effects were associated with induction of apoptosis and the inhibition of cell growth in HepG2 cells. This combination might therefore be an effective regimen for the chemoprevention and chemotherapy of HCC.
Chemopreventive anti-cancer agent acyclic retinoid suppresses allogeneic immune responses in rats

Ichiro Ohsawa,Takashi Murakami,Lei Guo,Shin Enosawa,Naoto Ishibashi,Shuji Isaji,Shinji Uemoto,Eiji Kobayashi

DOI: https://doi.org/10.1016/j.intimp.2010.04.017

Abstract:Acyclic retinoid NIK-333 (ACR) is a chemopreventive agent that acts by suppressing the recurrence of hepatocellular carcinoma (HCC) following initial treatment and is now being employed in clinical trials. The chemopreventive effects of ACR have been analyzed from various aspects, and it is well known that some retinoic acid (RA) derivatives affect host immunity. The objective of this study is to investigate the effects of ACR on host immunity. The results demonstrated that ACR prolonged heart and liver graft and recipient survival in rat allogeneic organ transplantation. The immunosuppressive effect of ACR administered at 100mg/kg/day was almost equivalent to that of CsA administered at 1mg/kg/day in vivo. In the mixed lymphocyte reaction (MLR), ACR suppressed lymphocyte proliferation non-specifically. Gene expression analysis of splenic lymphocytes from ACR-treated recipient rats revealed no distinct change in Interleukin (IL)-2 and increases in Interferon (IFN)-gamma. In conclusion, ACR possesses immunosuppressive potential in vivo and is a promising chemopreventive drug for long term use against HCC.
Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand

Tomohiko Ohno,Yohei Shirakami,Masahito Shimizu,Masaya Kubota,Hiroyasu Sakai,Yoichi Yasuda,Takahiro Kochi,Hisashi Tsurumi,Hisataka Moriwaki

DOI: https://doi.org/10.1016/j.canlet.2012.04.015

2012-10-28

Abstract:Abnormalities in the expression and function of retinoid X receptor (RXR), a master regulator of the nuclear receptor superfamily, are associated with the development of hepatocellular carcinoma (HCC). Dysfunction of farnesoid X receptor (FXR), one of the nuclear receptors that forms a heterodimer with RXR, also plays a role in liver carcinogenesis. In the present study, we examined the effects of acyclic retinoid (ACR), a synthetic retinoid targeting RXRα, plus GW4064, a ligand for FXR, on the growth of human HCC cells. We found that ACR and GW4064 preferentially inhibited the growth of HLE, HLF, and Huh7 human HCC cells in comparison with Hc normal hepatocytes. The combination of 1μM ACR plus 1μM GW4064 synergistically inhibited the growth of HLE cells by inducing apoptosis. The combined treatment with these agents acted cooperatively to induce cell cycle arrest in the G(0)/G(1) phase and inhibit the phosphorylation of RXRα, which is regarded as a critical factor for liver carcinogenesis, through inhibition of ERK and Stat3 phosphorylation. This combination also increased the expression levels of p21(CIP1) and SHP mRNA, while decreasing the levels of c-myc and cyclin D1 mRNA in HLE cells. In addition, a reporter assay indicated that the FXRE promoter activity was significantly increased by treatment with ACR plus GW4064. Our results suggest that ACR and GW4064 cooperatively inhibit RXRα phosphorylation, modulate the expression of FXR-regulated genes, thus resulting in the induction of apoptosis and the inhibition of growth in HCC cells. This combination might therefore be effective for the chemoprevention and chemotherapy of HCC.
Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1

Masumi Suzui,Muneyuki Masuda,Jin T E Lim,Chris Albanese,Richard G Pestell,I Bernard Weinstein

2002-07-15

Abstract:Acyclic retinoid (ACR), a novel synthetic retinoid, can prevent the recurrence of human hepatoma after surgical resection of primary tumors, but the molecular mechanisms by which ACR exerts antitumor effects are not known. In this study, we found that ACR inhibited the growth of three human hepatoma cell lines. In HepG2 cells, this inhibition was associated with an arrest of the cell cycle in G(0)-G(1), increased cellular levels of p21(CIP1), decreased levels of the hyperphosphorylated form of the retinoblastoma protein, and decreased levels of cyclin D1, but no significant changes were seen in the levels of the p16(INK4a), p27(KIP1), cyclin-dependent kinase 4, cyclin-dependent kinase 6, glycogen synthase kinase 3beta, or beta-catenin proteins. ACR also caused a decrease in the level of cyclin D1 mRNA. Cotreatment of HepG2 human hepatoma cells with the proteasome inhibitor N-acetyl-Leu-Leu-norleu-al did not prevent the ACR-induced decrease in cyclin D1 protein, in contrast to the protective effect of N-acetyl-Leu-Leu-norleu-al on the cyclin D1 protein in cells treated with all-trans-retinoic acid. In transient transfection reporter assays, ACR, but not all-trans-retinoic acid, inhibited transcription from the cyclin D1 promoter. As reported previously in colon carcinoma cells, we found that in hepatoma cells, cyclin D1 promoter activity is markedly stimulated by the beta-catenin/T-cell factor pathway. Nevertheless, even in the presence of excess beta-catenin, ACR markedly inhibited the transcriptional activity of the cyclin D1 promoter. This is the first systematic study of the inhibitory effects of ACR, or any other retinoid compound, on beta-catenin/T-cell factor-stimulated cyclin D1 promoter activity in human tumor cells. These novel effects of ACR provide further evidence that ACR may be a valuable agent in the chemoprevention and therapy of hepatoma and possibly other human malignancies.
The effect of acyclic retinoid on the metabolomic profiles of hepatocytes and hepatocellular carcinoma cells

Xian-Yang Qin,Feifei Wei,Masaru Tanokura,Naoto Ishibashi,Masahito Shimizu,Hisataka Moriwaki,Soichi Kojima

DOI: https://doi.org/10.1371/journal.pone.0082860

IF: 3.7

2013-12-23

PLoS ONE

Abstract:Background/purpose: Acyclic retinoid (ACR) is a promising chemopreventive agent for hepatocellular carcinoma (HCC) that selectively inhibits the growth of HCC cells (JHH7) but not normal hepatic cells (Hc). To better understand the molecular basis of the selective anti-cancer effect of ACR, we performed nuclear magnetic resonance (NMR)-based and capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS)-based metabolome analyses in JHH7 and Hc cells after treatment with ACR. Methodology/principal findings: NMR-based metabolomics revealed a distinct metabolomic profile of JHH7 cells at 18 h after ACR treatment but not at 4 h after ACR treatment. CE-TOFMS analysis identified 88 principal metabolites in JHH7 and Hc cells after 24 h of treatment with ethanol (EtOH) or ACR. The abundance of 71 of these metabolites was significantly different between EtOH-treated control JHH7 and Hc cells, and 49 of these metabolites were significantly down-regulated in the ACR-treated JHH7 cells compared to the EtOH-treated JHH7 cells. Of particular interest, the increase in adenosine-5'-triphosphate (ATP), the main cellular energy source, that was observed in the EtOH-treated control JHH7 cells was almost completely suppressed in the ACR-treated JHH7 cells; treatment with ACR restored ATP to the basal levels observed in both EtOH-control and ACR-treated Hc cells (0.72-fold compared to the EtOH control-treated JHH7 cells). Moreover, real-time PCR analyses revealed that ACR significantly increased the expression of pyruvate dehydrogenase kinases 4 (PDK4), a key regulator of ATP production, in JHH7 cells but not in Hc cells (3.06-fold and 1.20-fold compared to the EtOH control, respectively). Conclusions/significance: The results of the present study suggest that ACR may suppress the enhanced energy metabolism of JHH7 cells but not Hc cells; this occurs at least in part via the cancer-selective enhancement of PDK4 expression. The cancer-selective metabolic pathways identified in this study will be important targets of the anti-cancer activity of ACR.
Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.

L. Benesova,Marek Minarik,D. Jancarikova,B. Belšánová,M. Pešek

2010-05-01

Anticancer Research

Abstract:BACKGROUND Concurrent presence of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients is relatively rare and their appearance is believed to be mutually exclusive. Tumours harbouring KRAS mutation are perceived as not being capable of response to tyrosine kinase inhibitor (TKI) therapy. PATIENTS AND METHODS This paper presents 5 case reports of patients with tumours harbouring multiple EGFR and/or KRAS mutations. There were 3 patients with EGFR mutations (2 x exon 19 deletions, 1 x L858R) combined with KRAS mutations (2 x Gly12Asp, 1 x Gly12Val), 1 patient with two EGFR mutations (exon 19 deletion + L858R) and 1 patient with two KRAS mutations (Ala11Pro + Gly12Val). RESULTS All EGFR(+)/KRAS(+) patients had initially showed positive response to TKI treatment. The EGFR(+)/EGFR(+) patient has exhibited strong rash and good response with the best survival, while the KRAS(+)/KRAS(+) patient did not respond to TKI therapy. CONCLUSION EGFR(+)/KRAS(+) combination does not necessarily pose a negative prediction. This is probably due to the multiclonal character of the tumour displaying partial response in the EGFR(+) subpopulation.
[Effects of food concentration on life history traits of Brachionus calyciflorus clones in Jinghu Lake].

Lili Dong,Y. Xi,Lei Zhang

2009-02-01

Abstract:Four Brachionus calyceflorus clones (clone A, B, C, and D) different in biochemical and genetic characteristics were collected from Jinghu Lake in summer, and their life history traits were studied at 25 degrees C under the conditions of feeding with 1.0 x 10(6), 2.0 x 10(6), 4.0 x 10(6) and 8.0 x 10(6) cells x L(-1) of Scenedesmus obliquus. The results showed that S. obliquus concentration had different effects on the survival rate and fecundity of different B. calyciflorus clones. Among the four clones, clone C had the shortest generation time, clone B had the longest generation time, life expectancy and average lifespan, and clone A had the highest percentage of mictic females in its offspring. No significant differences were observed in the net reproductive rate and individual fitness among the four clones. At 2.0 x 10(6) cells x L(-1) of S. obliquus, the net reproductive rate of B. calyceiflorus was the lowest; at 1.0 x 10(6) cells x L(-1) of S. obliquus, B. calyciflorus had the shortest average lifespan and life expectancy but the highest mictic rate in its offspring; at 8.0 x 10(6) cells x L(-1) of S. obliquus, B. calyciflorus had the highest intrinsic rate of population increase and the longest average lifespan and life expectancy; and at 4.0 and 8.0 x 10(6) cells x L(-1) of S. obliquus, the individual fitness of B. calyciflorus was the highest. Clone C had the smallest individual fitness at 3.9 x 10(6) cells x L(-1) of S. obliquus and clone D had the highest one at 6. 34 x 10(6) cells x L(-1) of S. obliquus, while the individual fitness of clones A and B was not correlated with S. obliquus concentration. After July, the disappearance of genetically different B. calyciflorus clones from Jinghu Lake might attribute to the variation of algal food concentration, and the similar individual fitness of the four clones might be one of the reasons that contribute to the coexistence of B. calyciflorus clones in Jinghu Lake in summer.
Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid

Xian-Yang Qin,Harukazu Suzuki,Masao Honda,Hikari Okada,Shuichi Kaneko,Ikuyo Inoue,Etsuko Ebisui,Kosuke Hashimoto,Piero Carninci,Keita Kanki,Hideki Tatsukawa,Naoto Ishibashi,Takahiro Masaki,Tomokazu Matsuura,Hiroyuki Kagechika,Kan Toriguchi,Etsuro Hatano,Yohei Shirakami,Goshi Shiota,Masahito Shimizu,Hisataka Moriwaki,Soichi Kojima

DOI: https://doi.org/10.1073/pnas.1802279115

2018-05-08

Abstract:Hepatocellular carcinoma (HCC) is a highly lethal cancer that has a high rate of recurrence, in part because of cancer stem cell (CSC)-dependent field cancerization. Acyclic retinoid (ACR) is a synthetic vitamin A-like compound capable of preventing the recurrence of HCC. Here, we performed a genome-wide transcriptome screen and showed that ACR selectively suppressed the expression of MYCN, a member of the MYC family of basic helix-loop-helix-zipper transcription factors, in HCC cell cultures, animal models, and liver biopsies obtained from HCC patients. MYCN expression in human HCC was correlated positively with both CSC and Wnt/β-catenin signaling markers but negatively with mature hepatocyte markers. Functional analysis showed repressed cell-cycle progression, proliferation, and colony formation, activated caspase-8, and induced cell death in HCC cells following silencing of MYCN expression. High-content single-cell imaging analysis and flow cytometric analysis identified a MYCN+ CSC subpopulation in the heterogeneous HCC cell cultures and showed that these cells were selectively killed by ACR. Particularly, EpCAM+ cells isolated using a cell-sorting system showed increased MYCN expression and sensitivity to ACR compared with EpCAM- cells. In a long-term (>10 y) follow-up study of 102 patients with HCC, MYCN was expressed at higher levels in the HCC tumor region than in nontumor regions, and there was a positive correlation between MYCN expression and recurrence of de novo HCC but not metastatic HCC after curative treatment. In summary, these results suggest that MYCN serves as a prognostic biomarker and therapeutic target of ACR for liver CSCs in de novo HCC.
ROR-α-1 Inhibits the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma MHCC97H Via Downregulation of Chemokine CXCL5.

Gao Liu,Zhang-Fu Yang,Pei-Yun Zhou,Cheng Zhou,Ruo-Yu Guan,Bao-Ye Sun,Jia Fan,Jian Zhou,Yong Yi,Shuang-Jian Qiu

DOI: https://doi.org/10.1016/j.cyto.2020.155004

IF: 3.926

2020-01-01

Cytokine

Abstract:Hepatocarcinogenesis is a complicated process that is affected by a variety of microenvironmental factors, such as secretory chemokines and cell-extracellular matrix (ECM). Retinoic acid receptor-related orphan receptor (ROR)-α has been shown to attenuate tumor invasiveness by inducing suppressive cell microenvironment, and its low expression was associated with a worse prognosis in HCC patients. In the present study, we attempted to investigate the role and mechanism of the dominant transcript of ROR-α, ROR-α-1, in HCC development and progression. Among the four transcripts (ROR-α-1/-2/-3/-4), overexpression of ROR-α-1 dramatically suppressed the capacity of MHCC97H cells to proliferate, migrate and invade. We analyzed the differentially expressed genes in ROR-α-1-overexpressed and non-overexpressed MHCC97H cells, performed Gene Ontology (GO) enrichment analysis on these differentially-expressed genes, and found out that factors involved in the tumor microenvironment and ECM are related to the anti-tumor effects of ROR-α-1. Among these factors, chemokine CXCL5 was significantly downregulated by ROR-α-1 overexpression. Overexpression of ROR-α-1 remarkably inhibited the capacity of HCC cells to proliferate, migrate, invade, and downregulated the protein levels of β-catenin, c-Myc, Cyclin D1, and N-cadherin, suggesting the tumor-suppressive role of ROR-α-1 in MHCC97H cells. Moreover, overexpression of CXCL5 dramatically attenuated the suppressive effects of cell proliferation, migration and invasion induced by ROR-α-1 overexpression in MHCC97H, suggesting that ROR-α-1 exerts its anti-tumor effects via downregulating CXCL5. In conclusion, we demonstrate the tumor-suppressive role of ROR-α-1 in MHCC97H cells and that ROR-α-1 might play a tumor-suppressive role via regulation of chemokine CXCL5.

The effect of nitrogen source and cysteine on the morphology, conidiation and a cell wall fraction of conidial and aconidial Neurospora crassa.

Acyclic retinoid in chemoprevention of hepatocellular carcinoma: Targeting phosphorylated retinoid X receptor-α for prevention of liver carcinogenesis

Role of acyclic retinoid in the chemoprevention of hepatocellular carcinoma: basic aspects, clinical applications, and future prospects

Intraperitoneal Rupture of Hepatic Hydatid Cyst Following Blunt Abdominal Trauma

Exploring the reactivity of N-alkynylated sulfoximines: [2 + 2]-cycloadditions.

Combination of acyclic retinoid with branched-chain amino acids inhibits xenograft growth of human hepatoma cells in nude mice

Pharmaceutical and nutraceutical approaches for preventing liver carcinogenesis: chemoprevention of hepatocellular carcinoma using acyclic retinoid and branched-chain amino acids

Retinoid roles in blocking hepatocellular carcinoma

Covert Channel Analysis of the Password-Capability System

Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells

Novel role of 4-hydroxy-2-nonenal in AIFm2-mediated mitochondrial stress signaling.

β-Carotene-Induced Changes in RARβ Isoform mRNA Expression Patterns Do Not Influence Lung Adenoma Multiplicity in the NNK-Initiated A/J Mouse Model

Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells

Chemopreventive anti-cancer agent acyclic retinoid suppresses allogeneic immune responses in rats

Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand

Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1

The effect of acyclic retinoid on the metabolomic profiles of hepatocytes and hepatocellular carcinoma cells

Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.

[Effects of food concentration on life history traits of Brachionus calyciflorus clones in Jinghu Lake].

Prevention of hepatocellular carcinoma by targeting MYCN-positive liver cancer stem cells with acyclic retinoid

ROR-α-1 Inhibits the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma MHCC97H Via Downregulation of Chemokine CXCL5.